Favorable responses to ICIs such as pembrolizumab have been reported in MMR-deficient, MMR-mutated, MSI-high, or high-tumor-mutational-burden mCRPC [327,328,329,330,331,332,333]. This evidence concerns the gene MRC1 and neoplasm.